In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss recent news about drug-resistant infections. Later, Paul Jannetto, Ph.D., director of the Clinical and Forensic Toxicology Lab, Clinical Mass Spectrometry Lab, and Metals Lab, joins Dr. Pritt for the deep dive segment. Together, they explore how diagnostics are shaping the future of therapeutics.

• New podcast format launch (00:25): Drs. Morice and Pritt introduce the exciting new format for “Answers From the Lab,” including the addition of in-depth expert segments.
• Drug-resistant infections (02:05): Discover how clinical diagnostics play a critical role in combating the growing threat of antibiotic resistance.
• Diagnostics’ role in advancing precision medicine (13:28): Learn how diagnostics, specifically drug monitoring, are advancing personalized therapies and contributing to better outcomes.

Note: Information in this post was accurate at the time of its posting.

Resources

• Therapeutics testing: A clear path to accurate answers
• Therapeutics testing at Mayo Clinic Laboratories
• WHO warns of widespread resistance to common antibiotics worldwide
• Tests for infectious disease detection and identification

Connect with Us

• Is there a question or topic you’d like us to explore in a future episode? Email us at mayocliniclabs@mayo.edu.
• Learn more about our hosts and guests and connect with them on social media.
  • Bobbi Pritt, M.D. Bio | LinkedIn
  • Bill Morice, M.D., Ph.D. Bio | LinkedIn
  • Paul Jannetto, Ph.D. Bio | LinkedIn